For research use only. Not Intended for Therapeutic Use!
|We would like to match the lowest price on market if possible.|
|SMILES:||COCCCOC1=C(OC)C=CC(C[[email protected]@H](C[[email protected]](N)[[email protected]@H](O)C[[email protected]@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1|
Aliskiren(CGP 60536) is a direct renin inhibitor with IC50 of 1.5 nM.
Aliskiren is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension. While used for high blood pressure, other better studied medications are typically recommended due to concerns of higher side effects and less evidence of benefit. In December 2011, Novartis halted a clinical trial of the drug after discovering increased incidence of nonfatal stroke, kidney complications, high blood potassium, and low blood pressure in people with diabetes and kidney impairment.